EMA Application withdrawn: Exulett — Pfizer Limited

View source ↗

Summary

EMA reports withdrawal of the Exulett application by Pfizer Limited for skin and soft tissue infections and staphylococcal infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Skin Diseases
• Soft Tissue Infections
• Staphylococcal Infections

Drugs mentioned

• Exulett (dalbavancin)

Snippet

Status: Application withdrawn. Therapeutic area: Skin Diseases, Infectious;Staphylococcal Infections;Soft Tissue Infections. MAH: Pfizer Limited. Decision date: 31/12/2009